Novo Nordisk Faces Mounting Challenges as Competition Intensifies
Novo Nordisk cuts 2026 sales outlook amid generic competition in India, U.S. price pressures, and Eli Lilly’s new…
Novo Nordisk Charts a New Strategic Direction Amid Challenges
Novo Nordisk navigates FDA warnings, partners with Hims & Hers for digital sales, and expands in South America…
Novo Nordisk Shares Face Mounting Regulatory and Market Challenges
Novo Nordisk receives FDA warning over safety reporting delays but secures a new sales channel for Ozempic and…
Novo Nordisk Faces Mounting Challenges on Pricing and Pipeline
Novo Nordisk slashes US prices for Ozempic, Wegovy, and Rybelsus to $675/month in 2027. Its new obesity drug,…
Maersk Disappoints Investors, Points to Continued Challenges in Shipping
Despite reporting better than expected third quarter results and narrowing the range for its yearly income estimate,…